Methods of treatment using sustained release sotalol forumalations
AssigneeThe Roshni Singh 2015 Trust
InventorBramah N. Singh
Life of this patent
Estimating the term…
Abstract
Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours.
Claims18
A method of treating a patient for an arrhythmia, the method comprising administering topically, rectally, orally, or parenterally a therapeutically effective amount of a sustained release composition of sotalol comprising a racemic mixture of D-sotalol and L-sotalol, or a pharmaceutically acceptable salt thereof, to the patient to provide sustained release of the sotalol for at least 24 hours to the patient, wherein the therapeutically effective amount provides reduced beta-blockade relative to a composition that does not include a racemic mixture of D-sotalol and L-sotalol, and lengthened cardiac repolarization.
A method of treating or preventing a cardiac arrhythmia in a patient, comprising:
- orally or rectally administering to the patient a therapeutically effective amount of a sustained release composition of a racemic mixture of D-sotalol and L-sotalol or a pharmaceutically acceptable salt thereof, wherein the sustained release is maintained for at least 24 hours, wherein the therapeutically effective amount provides reduced beta-blockade relative to a composition that does not include a racemic mixture of D-sotalol and L-sotalol, and lengthened cardiac repolarization,
- wherein the racemic mixture of D-sotalol and L-sotalol or pharmaceutically acceptable salt thereof is the sole active ingredient of the sustained release composition.
A method of treating arrhythmias in a patient, the method comprising:
- administering topically, rectally, orally, or parenterally a therapeutically effective amount of a sustained release sotalol composition comprising:
- a racemic mixture of D-sotalol and L-sotalol, or a pharmaceutically acceptable salt thereof,
- wherein administering provides sustained release of the sotalol for at least 24 hours to the patient, and provides reduced beta-blockade relative to non-racemic sotalol, and lengthened cardiac repolarization,
- wherein the racemic mixture of D-sotalol and L-sotalol, or a pharmaceutically acceptable salt thereof is the sole active ingredient of the composition.
Dependencies are inferred from the claim text.